Hydroflumethiazide

CHEMBL1763 Phase 4 अनुमोदित Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
331.3 g/mol
LogP
0.4
Phase
4

A thiazide diuretic used to treat high blood pressure and edema by increasing urinary sodium and water excretion from the kidneys, reducing blood volume and relaxing blood vessel walls. It may be used alone or in combination with other antihypertensive agents for better blood pressure control. Monitoring of electrolytes, particularly potassium, is recommended during treatment.

आणविक भार

331.3000 g/mol

LogP

0.40

TPSA

135.00 Ų

लिपिंस्की RO5

उत्तीर्ण

चिकित्सीय क्षेत्र

क्रिया का तंत्र

Provides essential ions for maintaining fluid balance, nerve conduction, muscle contraction, and acid-base homeostasis. Supplementation corrects electrolyte imbalances.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

तंत्र

Provides essential ions for maintaining fluid balance, nerve conduction, muscle contraction, and acid-base homeostasis. Supplementation corrects electrolyte imbalances.

2D संरचना

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

NS(=O)(=O)c1cc2c(cc1C(F)(F)F)NCNS2(=O)=O

InChI

InChI=1S/C8H8F3N3O4S2/c9-8(10,11)4-1-5-7(2-6(4)19(12,15)16)20(17,18)14-3-13-5/h1-2,13-14H,3H2,(H2,12,15,16)

Molecular Formula

C8H8F3N3O4S2

HBD / HBA

3 / 10

घूर्णनीय बंधन

1

भारी परमाणु

20

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

अक्सर पूछे जाने वाले प्रश्न

A thiazide diuretic used to treat high blood pressure and edema by increasing urinary sodium and water excretion from the kidneys, reducing blood volume and relaxing blood vessel walls. It may be used alone or in combination with other antihypertensive agents for better blood pressure control. Monitoring of electrolytes, particularly potassium, is recommended during treatment.

Provides essential ions for maintaining fluid balance, nerve conduction, muscle contraction, and acid-base homeostasis. Supplementation corrects electrolyte imbalances.

Yes, Hydroflumethiazide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1763. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3647. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

चिकित्सा अस्वीकरण

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.